EGFR and neoplasm: For example, the use of proteolysis-targeting chimeras (PROTACs) to degrade EGFR L858R has been shown to downregulate PD-L1 and indoleamine 2,3-dioxygenase 1 protein levels, thereby amplifying anti-tumor immune responses and providing an approach to NSCLC immunotherapy (113).